SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( ...
Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback